Our Psychedelic Trip Isn’t Over I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
cmps.q
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release. If you’re not entirely sure what an ETF…
‘Cybin is the only green stock in my portfolio’ – r/shroomstocks Cybin (CYBN.NE) started out June 1st at $1.71 CAD and has since launched up to $2.72, a 60%…
Big ass IPO? Not really… ‘Shares soar as Atai Life Sciences IPO’s on the Nasdaq’ is the story being spun around Atai’s (ATAI.Q) first crack at going public last…
A study was published today in the New England Journal of Medicine which tested COMPASS Pathways’ (CMPS.Q) COMP360 psilocybin. The study is a phase II double-blind, randomized, controlled trial…
It’s 2031, COVID is long gone. Jose Conseco is president of the USA. Jeff Bezos redesigns the human digestive system to not need food or water Peter Thiel spends…
“Life is too short to be small.” – Tim Ferriss, The 4-Hour Workweek Every psychedelics company starts its investor deck off with a fact about the quickly changing regulatory…